SCHEMBL851097

SCHEMBL851097

COC(=O)c1ccc(F)c(O)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.69
CA2 P00918 4/20 0.69
CA12 O43570 3/20 0.69
CA7 P43166 3/20 0.69
CA9 Q16790 3/20 0.69
CA14 Q9ULX7 3/20 0.69
XDH P47989 2/20 0.69
KDM4E B2RXH2 3/20 0.62
LMNA P02545 2/20 0.62
GAA P10253 2/20 0.62
TDP1 Q9NUW8 2/20 0.62
POLB P06746 1/20 0.62
NFKB1 P19838 1/20 0.62
GFER P55789 1/20 0.62
NFKB2 Q00653 1/20 0.62
RELA Q04206 1/20 0.62
FUT7 Q11130 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
MAPT P10636 3/20 0.56
MEN1 O00255 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29433261 1.00 CA1 (0.69) CA1CA2CA12CA7CA9
SCHEMBL16844649 0.86 EGFR (0.63) CA1CA2CA12CA7CA9
SCHEMBL199239 0.85 CA1 (0.69) CA1CA2CA12CA7CA9
SCHEMBL29664708 0.84 CES2 (0.59) CA1CA2CA12CA7CA9
SCHEMBL14012582 0.84 CES2 (0.59) CA1CA2CA12CA7CA9
SCHEMBL383936 0.84 CES2 (0.59) CA1CA2CA12CA7CA9
SCHEMBL13738767 0.82 ERN1 (0.64) CA1CA2CA12CA7CA9
Methyl Protocatechuate SCHEMBL29360855 0.82 CA1 (1.00) CA1CA2CA12CA7CA9
Methyl Protocatechuate SCHEMBL38624 0.82 CA1 (1.00) CA1CA2CA12CA7CA9
SCHEMBL15099889 0.82 CA1 (0.77) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060205807-A1 Amino-chroman compounds and methods for preparing same WYETH (US) 2006-09-14 US claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
EP-4635494-A2 AMIDO HETEROAROMATIC COMPOUNDS Astrazeneca AB (SE) 2025-10-22 EP disclosed
US-20250313534-A1 PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF ALTER DOMUS (US) LLC, AS COLLATERAL AGENT 2025-10-09 US disclosed
US-20250304603-A1 OXABOROLE ESTERS AND USES THEREOF ANACOR PHARMACEUTICALS INC (US) 2025-10-02 US disclosed
EP-4514782-B1 AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES ASTRAZENECA AB (SE) 2025-09-10 EP disclosed
US-20250186399-A1 Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2025-06-12 US disclosed
US-20250179026-A1 Deuterium-Enriched 3,5-Dimethylpyrazolyl-3-propoxy-4-fluorobenzoic Acids for Treatment of Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) and Polyneuropathy (ATTR-PN), and Related Diseases DHANOA DALJIT SINGH (US) 2025-06-05 US disclosed
US-12291524-B2 Amido heteroaromatic compounds ASTRAZENECA AB (SE) 2025-05-06 US disclosed
US-20050032873-A1 3-Amino chroman and 2-amino tetralin derivatives WYETH (US) 2005-02-10 US disclosed
WO-2005012291-A1 3-AMINO CHOMAN AND 2-AMINO TETRALIN DERIVATIVES WYETH (US) 2005-02-10 WO disclosed
CN-1481376-A HYDROXYBENZAMIDE DERIVATIVES AS FACTOR XA INHIBITORS ���ĵ�˹ҩ��¹����޹�˾ 2004-03-10 CN disclosed
EP-1349847-A1 OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS Aventis Pharma Deutschland GmbH (DE) 2003-10-08 EP disclosed
US-20020198195-A1 New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2002-12-26 US disclosed
WO-2002051831-A1 OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-07-04 WO disclosed
EP-0975618-B1 a new process for the preparation of 3-N,N-dicycobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide ASTRAZENECA AB (SE) 2001-10-24 EP disclosed
US-6197978-B1 ESTERIFICATION, PROPARYLATION, HEATING, HYDROLYSIS, ETHERIFICATION, REDUCTION, ALKYLATION, CYCLIZATION, AMINATION ASTRA AKTIEBOLAG (SE) 2001-03-06 US disclosed
EP-0975618-A1 A NEW PROCESS Astra Aktiebolag (SE) 2000-02-02 EP disclosed
WO-1998046586-A1 A NEW PROCESS ASTRA AKTIEBOLAG (SE) 1998-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12291524-B2 Amido heteroaromatic compounds CYP7A1, SLC10A1, CYP11B2 CA1 4103/4885CA2 4242/4885CA12 3210/4885
US-20250304603-A1 OXABOROLE ESTERS AND USES THEREOF OXA1L, HSD17B12, OXER1 CA1 3605/4885CA2 2852/4885CA12 1813/4885
US-20050032873-A1 3-Amino chroman and 2-amino tetralin derivatives TPH2, HTR2C, HTR7 CA1 1325/4885CA2 1863/4885CA12 3012/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH CA1 2762/4885CA2 2217/4885CA12 3802/4885
US-20250186399-A1 Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions TTR, PRNP, APP CA1 4516/4885CA2 4760/4885CA12 4680/4885
US-20250179026-A1 Deuterium-Enriched 3,5-Dimethylpyrazolyl-3-propoxy-4-fluorobenzoic Acids for Treatment of Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) and Polyneuropathy (ATTR-PN), and Related Diseases TTR, TNNT2, TNNI3 CA1 4847/4885CA2 4504/4885CA12 4827/4885
US-20020198195-A1 New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa F9, F11, F5 CA1 4325/4885CA2 2450/4885CA12 3684/4885
US-20250313534-A1 PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF UGT1A10, SAMM50, AGL CA1 1466/4885CA2 2227/4885CA12 441/4885
US-20060205807-A1 Amino-chroman compounds and methods for preparing same AAAS, CDYL, BCAT1 CA1 2084/4885CA2 2519/4885CA12 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.